MK-677vsSLU-PP-332

MK-677 (Ibutamoren) is a non-peptide spiropiperidine compound that functions as a potent, orally active agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a). Unlike peptide-based GH secretagogues that require injection, MK-677 is resistant to gastrointestinal degradation and has excellent oral bioavailability, making it unique among compounds that stimulate GH release through the ghrelin receptor.

Upon binding GHS-R1a in the anterior pituitary, MK-677 activates the Gq/11-coupled PLC/IP3/calcium signaling pathway, triggering GH vesicle exocytosis. It also acts on GHS-R1a receptors in the hypothalamus, stimulating GHRH neurons in the arcuate nucleus while suppressing somatostatin tone, further amplifying the GH secretory signal. Importantly, MK-677 preserves the endogenous pulsatile pattern of GH release — it amplifies pulse amplitude rather than creating a flat, sustained elevation.

The 24-hour half-life means a single daily dose maintains elevated GH and IGF-1 levels around the clock. In clinical studies, MK-677 increased IGF-1 levels by 40-60% in elderly subjects, with sustained effects over 12 months without significant tachyphylaxis. However, its ghrelin-mimetic activity also activates hypothalamic appetite circuits (orexigenic neurons expressing NPY/AgRP), producing the notable increase in hunger that many users report. The compound also has mild cortisol-raising effects and can impair insulin sensitivity with prolonged use, likely through sustained GH-mediated antagonism of insulin signaling in peripheral tissues. Despite promising clinical data for muscle wasting and osteoporosis, MK-677 has not completed the FDA approval process.

SLU-PP-332 is a small molecule agonist of estrogen-related receptor alpha (ERRα), one of three orphan nuclear receptors in the ERR family. Despite its name, ERRα does not bind estrogen — it was named for its structural similarity to estrogen receptors. ERRα is constitutively active and functions as a master transcription factor for genes controlling mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation, particularly in metabolically active tissues like skeletal muscle, heart, and brown adipose tissue.

SLU-PP-332 enhances ERRα transcriptional activity by stabilizing its active conformation and promoting coactivator recruitment (particularly PGC-1α, which is both an ERRα target gene and an ERRα coactivator, creating a positive feed-forward loop). Activated ERRα binds to ERR response elements (ERREs) in the promoter regions of hundreds of metabolic genes, upregulating the entire oxidative metabolism gene program: mitochondrial electron transport chain subunits, fatty acid oxidation enzymes, TCA cycle enzymes, and mitochondrial transcription and replication factors.

The most striking effect in preclinical studies is the transformation of skeletal muscle fiber type composition. SLU-PP-332 treatment increases the proportion of slow-twitch (type I) and oxidative fast-twitch (type IIA) fibers while decreasing glycolytic fast-twitch (type IIB/IIX) fibers. Type I fibers are rich in mitochondria, capillaries, and myoglobin — they are the fibers that endurance athletes develop through years of training. By pharmacologically shifting this fiber type ratio, SLU-PP-332 produces endurance capacity gains similar to what would require months of aerobic training. In mouse studies published in 2023, treated animals ran significantly longer and farther on treadmill tests. This ERRα-mediated mechanism is distinct from and potentially complementary to AMPK-based exercise mimetics like AICAR, as it targets a different node in the mitochondrial biogenesis regulatory network.